Home > Focus On
THE ITALIAN PHARMACEUTICAL INDUSTRY MAJOR EUROPEAN PLAYERS IN INNOVATION AND R&D
174 factories, providing 63500 jobs to employees, with EUR €2.4 bn. in investments (half of which are destined for R&D), and production equal to €26 bn. – some 67% destined for export, which has grown 44% over the last 5 years compared to the 7% average across the manufacturing industry as a whole. This is the snapshot of the Italian pharmaceuticals industry taken by the "Farmindustria" pharmaceuticals industry association. Lombardy, with 30 000 employees, to which are added 16000 in ancillary industries, is the "leader" in Italian pharmaceuticals and biotechnology, followed by Lazio (14000), with Campania (700 employees; 3000 including ancillary industries) and Sicily (approx. 1000 employees, with 2000 in ancillary industries).
Growth in the pharmaceuticals industry is coming primarily from biotech: in Italy, there is in fact a 'pipeline' of 359 biotech products in the system, between SMEs and pharmaceuticals businesses, to which we can add 67 'discovery' projects.
Investments in innovation, and in R&D place the Italian pharmaceuticals industry up with the major players in Europe, with a 24% share of production and 18% market share overall.
Among the many factors which might render the Italian market less attractive to the major multinational players when launching new pharmaceuticals are the more difficult launch requirements compared to other EU players: according to data provided by Farmindustria, the period from 2010 to 2012 saw EMA (the European Medicines Agency) approve only 14 new pharmaceuticals, whereas Germany approved 39 over the same period. T
he average delay for the introduction of a pharmacy in the first country is 300 days.
Despite this, and despite the cuts that are impacting the national market, the President of Farmindustria, Massimo Scaccabarozzi, explains: "It is not true that multinationals are beating a retreat."
"Foreign groups are still very active in Italy and they are investing," Scaccabarozzi added. "For example, Jannsen, the company I work for, has invested 80 million Euros in its Latina site, creating 300 new jobs in a deprived area.
These same foreign groups export 70% of what they produce in the country, which is an important point when you consider that the sector's overall exports (including both Italian and foreign-owned businesses) has increased by 44% over the last five years, while the internal market has fallen 5.5%."
To this analysis, we add another, regarding the vitality of Italian-owned businesses, which, as Scaccabarozzi states, "have made huge investments in Italy, and acquisitions abroad, demonstrating their commitment despite the crisis."